Evidence map›Paper›PMID 26318427›Full record

ReviewOncotarget2015

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Giuseppe Bronte, Nicola Silvestris, Marta Castiglia, Antonio Galvano, Francesco Passiglia, Giovanni Sortino, Giuseppe Cicero, Christian Rolfo, Marc Peeters, Viviana Bazan and 3 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Giuseppe BronteDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Nicola SilvestrisMedical Oncology Unit,National Cancer Institute "Giovanni Paolo II", Bari, Italy.
Marta CastigliaDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Antonio GalvanoDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Francesco PassigliaDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Giovanni SortinoDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Giuseppe CiceroDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Christian RolfoDepartment of Oncology, University Hospital of Antwerp, Edegem, Belgium.
Marc PeetersDepartment of Oncology, University Hospital of Antwerp, Edegem, Belgium.
Viviana BazanDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Daniele FanaleDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Antonio GiordanoSbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA.
Antonio RussoDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
University of Palermo · ITAntwerp University Hospital · BEIstituto Tumori Bari · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor DNA, is an innovative method to study both primary and acquired resistance to anti-EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to enable the identification of a wide set of gene mutations related to resistance.

Indexed as

Antibodies, MonoclonalAntineoplastic AgentsCetuximabColorectal NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsGTP PhosphohydrolasesHumansMembrane ProteinsMutationNeoplasm MetastasisPanitumumabProto-Oncogene Proteins p21(ras)Antibodies, MonoclonalAntineoplastic AgentsCetuximabEGFR protein, humanErbB ReceptorsGTP PhosphohydrolasesKRAS protein, humanMembrane ProteinsNRAS protein, humanPanitumumabProto-Oncogene Proteins p21(ras)cetuximabcolorectal cancerepidermal growth factor receptorpanitumumabRAS

Identifiers

PMID26318427
PMCPMC4694794
OpenAlexW2098352219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.